MAPT and Alzheimer disease: Furthermore, we determined cut-offs for CSF biomarkers of AD (Aβ42, T-tau, and P-tau) and their ratios measured on the fully automated Lumipulse and Elecsys to optimize their concordance with Aβ42/40 status.